FDA advisory panelist outlines issues with aducanumab's approval for Alzheimer's disease
Despite near unanimous objection from its advisory panel, the U.S. Food and Drug Administration (FDA) granted aducanumab approval to treat Alzheimer's disease on June 7, 2021. In a commentary published in Annals of Internal ...
Jun 18, 2021
0
1